CPT 11 (Irinotecan), DNA topoisomerase I inhibitor (ab141107)
- Datasheet
- References
Overview
-
Product nameCPT 11 (Irinotecan), DNA topoisomerase I inhibitor
-
DescriptionPotent DNA topoisomerase I inhibitor
-
Alternative names
- Irinotecan Hydrochloride
-
Biological descriptionPotent DNA topoisomerase I inhibitor. Displays antitumor activity against a variety of tumor types. Active metabolite SN38 (ab141108) also available.
-
Purity> 99%
Properties
-
Chemical name(4S)-4,11-Diethyl-3,4,12,14-tetrahydro-4-hydroxy-3,14-dioxo-1H-pyrano[3',4':6,7]indolizino[1,2-b]quinolin-9-yl [1,4'-bipiperidine]-1'-carboxylic acid ester hydrochloride
-
Molecular weight623.15
-
Chemical structure
-
Molecular formulaC33H38N4O6.HCl
-
CAS Number100286-90-6
-
PubChem identifier74990
-
Storage instructionsStore at +4°C. The product can be stored for up to 12 months.
-
Solubility overviewSoluble in water to 25 mM and in DMSO to 100 mM
-
Handling
Wherever possible, you should prepare and use solutions on the same day. However, if you need to make up stock solutions in advance, we recommend that you store the solution as aliquots in tightly sealed vials at -20°C. Generally, these will be useable for up to one month. Before use, and prior to opening the vial we recommend that you allow your product to equilibrate to room temperature for at least 1 hour.
Need more advice on solubility, usage and handling? Please visit our frequently asked questions (FAQ) page for more details.
-
SMILESCl.CC[C@]3(O)C=4C=C5c6nc7ccc(OC(=O)N1CCC(CC1)N2CCCCC2)cc7c(CC)c6CN5C(=O)C=4COC3=O
-
Source
Synthetic
-
Research areas
Applications
Our Abpromise guarantee covers the use of ab141107 in the following tested applications.
The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.
| Application | Abreviews | Notes |
|---|---|---|
| Functional Studies | Use at an assay dependent concentration. |
Images
-
Functional Studies - CPT 11 (Irinotecan) (ab141107)ab2893 staining γH2A.X in HeLa cells treated with CPT 11 (Irinotecan) (ab141107), by ICC/IF. Increase of γH2A.X nuclear expression correlates with increased concentration of CPT 11 (Irinotecan), as described in literature.
The cells were incubated at 37°C for 6 hours in media containing different concentrations of ab141107 (CPT 11 (Irinotecan)) in DMSO, fixed with 100% methanol for 5 minutes at -20°C and blocked with PBS containing 10% goat serum, 0.3 M glycine, 1% BSA and 0.1% tween for 2h at room temperature. Staining of the treated cells with ab2893 (5 µg/ml) was performed overnight at 4°C in PBS containing 1% BSA and 0.1% tween. A DyLight 488 anti-rabbit polyclonal antibody (ab96899) at 1/250 dilution was used as the secondary antibody. Nuclei were counterstained with DAPI and are shown in blue.
References
This product has been referenced in:
- Albertsson P et al. Low-dosage metronomic chemotherapy and angiogenesis: topoisomerase inhibitors irinotecan and mitoxantrone stimulate VEGF-A-mediated angiogenesis. APMIS 120:147-56 (2012). Read more (PubMed: 22229270) »
- Morton CL et al. Activation and antitumor activity of CPT-11 in plasma esterase-deficient mice. Cancer Chemother Pharmacol 56:629-36 (2005). Read more (PubMed: 15918039) »
- Vassal G et al. Therapeutic activity of CPT-11, a DNA-topoisomerase I inhibitor, against peripheral primitive neuroectodermal tumour and neuroblastoma xenografts. Br J Cancer 74:537-45 (1996). Read more (PubMed: 8761367) »
